Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

DOI: 10.1371/journal.pone.0200996

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text